US Patent

US7425637 — N3 alkylated benzimidazole derivatives as MEK inhibitors

Composition of Matter · Assigned to Array Biopharma Inc · Expires 2028-03-13 · 2y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a class of compounds, including selumetinib sulfate, that inhibit MEK and are useful in treating hyperproliferative diseases in mammals.

USPTO Abstract

Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R<SUP>1</SUP>, R<SUP>2</SUP>, R<SUP>7</SUP>, R<SUP>8</SUP>, R<SUP>9 </SUP>and R<SUP>10 </SUP>are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.

Drugs covered by this patent

Patent Metadata

Patent number
US7425637
Jurisdiction
US
Classification
Composition of Matter
Expires
2028-03-13
Drug substance claim
Yes
Drug product claim
No
Assignee
Array Biopharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.